TopoTarget A/S

Find more results for TOPO

Officers and directors

Bo Jesper Hansen M.D., Ph.D.
Executive Independent Chairman of the Board
Lone Dahl
Director of Finance
Elisabeth V. Carstensen
Director of Pharmaceutical Operations
Anne V. Sillemann
Director of Global Regulatory Affairs
Jette Tjoernelund
Director of Science
Per Samuelsson
Non-Independent Director
Jeffrey H. Buchalter
Independent Director
Anker Lundemose M.D., Ph.D.
Independent Director
Ingelise Saunders
Independent Director
Gisela Schwab M.D.
Independent Director


c/o Symbion Fruebjergvej 3, Koebenhavn OE

Website links

Topotarget A/S is a Denmark-based biopharmaceutical company focused on the field of oncology. The Company is engaged in the development of cancer therapies, focusing primarily on the development of its principal drug candidate, Belinostat. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within peripheral T-cell lymphoma (PTCL) and phase II in cancer of unknown primary (CUP). It works in partnerships with Spectrum Pharmaceuticals Inc., Multimeric Biotherapeutics Inc. and the National Cancer Institute. As of December 31, 2011, the Company had five wholly owned subsidiaries, namely Topotarget UK Limited, Topotarget Germany AG, Topotarget USA Inc., Topotarget Switzerland S.A. and Topotarget Netherlands B.V. The Company’s two largest shareholders are HealthCap funds and Avanza bank. In April 2014, combined holdings of Topotarget A/S shares for all relevant HealthCap entities (HealthCap III and HealthCap IV) were reduced below 10%.